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strategy of best medical management alone. The authors developed a
Markov transition model to model disease progression and use of resources
for both CEA combined with best medical management or the strategy of
best medical management alone. The model was based on data from the
randomized asymptomatic carotid surgery trial (ACST), a National Swedish
Vascular Database, and expected costs and health outcomes in terms of
quality adjusted life years (QALYs). Cost effectiveness was established for a
Swedish setting from the Swedish societal perspective.
(Base-case analysis showed incremental cost per QALY of CEA for a
65- and 75- year old man/woman was 34,557 Euros and 311,133 Euros
and 58,930 Euros and 779,776 Euros respectively. A sensitivity analysis
indicated that a duration of treatment effect of five years was important for
the cost effectiveness results. An additional five-year duration of treatment
effect (10 years total) indicated that the cost in Euros per QALY gained from
CEA was 13,748 for men age 65 years and 31,384 for men age 75 years. For
an additional 10 year duration of treatment effect (15 years total) the cost
per QALY gained from CEA for a 65 year old man was 8,707 Euros and for
a 75 year old man, 26,315 Euros. Fifteen year total treatment effect in
women 65 years of age was at a projected cost of 46,421 Euros per QALY
and for a woman 75 years of age, it was 114,936 Euros per QALY.
Comment: It is estimated 34,557 Euros per QALY gained for a 65 year
old man is cost effective. At age 73 years, for men, the cost per QALY gained
with CEA was near the implicit willingness to pay for a QALY in Sweden. It
indicates that men age 73 years of age gain enough from CEA to justify
risks of CEA and high initial costs. In women, it is only those 65 years of age
or under at the time of CEA and who live 15 years who will benefit from
prophylactic CEA from a cost effective viewpoint. The data are obviously
interesting but it seems politically untenable to deny women, and not men,
prophylactic CEA for high-grade asymptomatic carotid stenosis.
Effects of Intensive Glucose Lowering in Type 2 Diabetes
The Action to Control Cardiovascular Risk in Diabetes Study Group. N
Engl J Med 2008;358:2545-59.
Conclusion: After 3.5 years intensive therapy to lower glycated hemo-
globin levels below standard recommendations in patients with Type 2
diabetes resulted in increased mortality and did not reduce major cardiovas-
cular events.
Summary: This is one of two 2 major randomized trials on glucose
lowering in patients with type 2 diabetes appearing in the June 12, 2008
issue of theNewEngland Journal ofMedicine (see also next abstract). In this
study, 10,251 patients with a mean age of 62.2 years and a median glycated
hemoglobin level of 8.1% were randomly assigned to intensive or standard
glucose control therapy. Intensive therapy targeted a glycated hemoglobin
level less than 6.0% while standard therapy targeted a level from 7.0 to 7.9%.
38% of the patients in this study were women and 35% of the patients had
had a previous cardiovascular event. Primary outcome was a composite of
non-fatal stroke, non-fatal myocardial infarction, or death from cardiovas-
cular causes. The study was stopped after 3.5 years by the safety monitoring
committee when it was found that there was a higher mortality in the
intensive therapy group.
Stable median glycated hemoglobin levels 6.4% and 7.5% were
achieved at one year in the intensive and standard therapy groups
respectively. The primary outcome occurred in 371 patients in the
standard therapy group and 352 patients in the intensive therapy group
(p0.16). There were 257 deaths in the intensive therapy group and 203
in the standard therapy group (hazard ratio 1.22; 95% CI, 1.01 to 1.46;
p0.04). Weight gains of more than 10 kilograms and hypoglycemia
requiring assistance were more frequent in the intensive therapy group
(p0.001).
Comment: This study and the Advance trial (see below) together,
randomized over 21,000 patients with type 2 diabetes to standard or
intensive diabetic control. While there was some potential hint of long term
benefit in microcardiovascular events in the Advance trial, this study identi-
fied a previously unrecognized harm of intensive glucose lowering in patients
with type 2 diabetes. Once again, when subject to the rigors of a randomized
trial, a commonly held belief appears to have been incorrect. These studies
will be intensely debated but the bottom line is there was no clear benefit
from intensive glucose control in reducing macrovascular events in patients
with type 2 diabetes.
Intensive Blood Glucose Control and Vascular Outcomes in Patients
with Type 2 Diabetes
The Advance Collaborative Group. N Engl J Med 2008;358:2560-2572.
Conclusion: Intensive glucose control in patients with type II diabetes
decreases nephropathy but has no effect on macrovascular events such as
death from cardiovascular causes, stroke or non- fatal myocardial infarcton.
Summary: The prevalence of Type 2 diabetes is increasing rapidly and
is associated with significant cardiovascular adverse effects. The authors
tested the hypothesis that, in patients with type II diabetes, intensive glucose
control as evidenced by lowering the glycated hemoglobin level to to6.5%
would result in lower rates of major microvascular and macrovascular events.
There were 11,140 patients with Type 2 diabetes who were randomly
assigned to undergo standard glucose control or intensive glucose control.
Intensive glucose control was achieved with the use of gliclazide (modified
release) and other drugs as required to reach a glycated hemoglobin6.5%.
Primary end points were composites of major microvascular events (new or
worsening nephropathy or retinopathy) or macrovascular events (death
from cardiovascular causes, non-fatal myocardial infarction, or non-fatal
stroke). End points were assessed both jointly and separately.
The mean glycated hemoglobin at a median follow-up of 5 years was
lower in the intensive control group (6.5%) than in the standard control
group (7.3%). The incidence of combined macrovascular and microvascular
events in the intensive control group was 18.1% v. 20.0% in the standard
control group (hazard ratio 0.90; 95% CI 0.82 to 0.98; p0.01). Major
microvascular events were 9.4% in intensive control and 10.9% in standard
control group (hazard ratio 0.86, 95% CE 0.77 to 0.97, p0.01). This
resulted primarily from a reduction in the incidence of nephropathy
(p0.006). There was no significant effect on retinopathy (p0.50). There
was also no significant effect of glucose control on major macrovascular
events (hazard ration with intensive control 0.94, 95% CI 0.84 to 1.06;
p0.32). There was no difference in death from cardiovascular causes
(p0.12) or death from any cause (p0.28). Significant hypoglycemia was
more common in the intensive control group (2.7% v. 1.5%, hazard ratio
1.86, 95% CI 1.42 to 2.40, p0.001).
Comment: It is disappointing that intensive glucose control did not
result in a reduction in macrocardiovascular events in patients with Type 2
diabetes. It may be, however, that longer follow-up is needed to detect such
an effect. The clear improvement in nephropathy, with longer follow up,
perhaps could be expected to have benefit over time in reducing macrovas-
cular events. This is, however, only speculation and the idea that intensive
glucose control is beneficial in patients with type II diabetes must be
seriously questioned. See also previous abstract.
ResourceUtilization and Economic Costs of Care Based on ARandom-
ized Trial of Vacuum-Assisted Closure Therapy in the Treatment of
Diabetic Foot Wounds
Apleqvist J, Armstrong DG, Lavery LA, et. al. Am J Surg 2008;195:792-
788.
Conclusion: In diabetic patients with post-amputation wounds, neg-
ative pressure wound therapy heals a greater proportion of patients with less
resource utilization than standard moist wound therapy.
Summary:There were 162 patients with diabetes and post-amputation
wounds entered into a 16 week randomized clinical trial. Seventy-seven
patients were randomized to negative pressure wound therapy NPWT) and
received dressing changes every 48 hours. Eighty-five patients received
standard moist wound (MWT) therapy according to consensus guidelines
(Wound Ostemy Continence Nursing Society. Guideline for Management
of Wounds in Patients with Lower Extremity Neuropathic Disease. WOCN
Glennville, IL; 2004: 57). Direct costs, procedures, and resource utilization
were analyzed in a post-op retrospective analysis.
In the NPWT v. MWT groups, there were no differences in inpatient
hospital stay either in terms of number of admissions or length of stay. There
were more debridement procedures required in theMWT group (120 v. 43,
p0.001). The average number of dressing changes per patient in theMWT
group was 118 (range 12-226) v. 41 (6-140) for NPWT, p0.0001. The
average direct cost per patient for 8 weeks of treatment or longer was
$27,220 for the NPWT group and $36,096 for the MWT group. The
average total cost to achieve healing was $25,954 in patients treated with
NPWT (n43) compared with $38,806 for the MWT group (n33).
Comment: It is very expensive to heal wounds. The study suggests
negative pressure therapy for open diabetic wounds is cheaper and more
effective than standard moist wound therapy. Costs in theMWT group were
driven primarily by dressing changes and antibiotic costs. It is likely that the
costs presented are conservative. Costs related to transportation, inpatient
dressing changes, prosthesis and rehabilitation were not included in the
analysis. Note the authors have affiliations with KCI, themanufacturer of the
negative pressure device used in this study.
Rivaroxaban vs Enoxaparin for Thromboprophylaxis after Hip
Arthroplasty
Eriksson BI, Borris LC, Friedman RJ. and the RECORDOne Study Group.
N Engl J Med 2008;358:2765-75.
Conclusion: In patients undergoing elective hip arthroplasty, an oral
dose of Rivaroxaban once daily is more effective than Enoxaparin for
extended thromboprophylaxis.
Summary: Extending thromboprophylaxis for five weeks following
total hip arthroplasty is more effective than short term thromboprophylaxis
in preventing venous thromboembolism (VTE). There is a Grade 1A rec-
ommendation by the American College of Chest Physicians for extended
thromboprophylaxis after hip arthroplasty.
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